5 research outputs found
Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer
An ideal cancer therapy targets the tumor cells selectively without
damaging healthy tissues. Even though the tumor-specific markers are
limited, these molecules can be used for the delivery of anti-cancer
drugs as an active targeting strategy. Since the lymphatic system plays
a critical role in the dissemination of cancer cells, the drugs directed
through lymphatics can feasibly reach to the sites of metastasis. LyP-1
is a peptide that binds to the p32 receptor which is highly expressed
not only on the lymphatic endothelium but also on the malignant cells;
thus, making this peptide ligand a preferable candidate to mediate
active targeting of lymphatics and cancer cells. In this study,
different formulations of LyP-1 containing lipid-based nanophannaceutics
so-called self-microemulsifying drug delivery systems (SMEDDS) were
developed and tested for their efficacy in targeting breast cancer.
Following the selection of non-toxic formulation, doxorubicin
hydrochloride and LyP-1 were co-administered in the SMEDDS, which
resulted in a significant increase in in vitro cytotoxicity in
p32-expressing breast cancer cells, 4T1 and MDA-MB-231. Accordingly, the
uptake of LyP-1 in the SMEDDS by the cancer cells was demonstrated. The
expression of p32 was detected in the 4T1 tumor tissues which were
efficiently targeted with LyP-1 in the SMEDDS. When doxorubicin was
co-administrated with LyP-1 in SMEDDS via intraperitonial
administration, tumor growth and metastasis were significantly reduced.
In conclusion, a novel and efficacious SMEDDS formulation containing
LyP-1 with a droplet size less than 100 nm was developed for the
lymphatic targeting of breast cancer